

Claims:

1. A composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one
5 discontinuous oil phase,
wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, and
wherein the composition has a pH of 7.75 ± 0.5 .
- 10 2. A composition according to claim 1, wherein the composition has a pH of 7.75 ± 0.25 .
3. A composition according to claim 1 wherein the composition comprises, by weight of the composition:
15 from 0.001 to 0.01 wt% calcipotriol; and/or
from 0.02 to 0.1 wt% betamethasone; and/or
from 0.001 to 0.005 wt% alpha-tocopherol; and/or
from 0.05 to 0.5 wt% butylated hydroxyanisole.
- 20 4. A composition according to any of the preceding claims wherein:
the calcipotriol is predominantly in at least one of said discontinuous oil phase(s); and/or
the betamethasone dipropionate is predominantly in at least one of said discontinuous oil phase(s); and/or
25 the alpha-tocopherol is predominantly in at least one of said discontinuous oil phase(s); and/or
the butylated hydroxyanisole is predominantly in at least one of said discontinuous oil phase(s).
- 30 5. A composition according to any of the preceding claims, wherein at least one of said discontinuous oil phase(s) comprises medium chain triglycerides and isopropyl myristate, wherein the isopropyl myristate and medium chain triglycerides are present in a weight ratio of from 3:1 to 12:1.
- 35 6. A composition according to any of the preceding claims, wherein the polyaphron dispersion further comprises a discontinuous phase comprising a non-solvent oil, preferably wherein the non-solvent oil is mineral oil.

7. A composition according to any of the preceding claims, wherein said discontinuous oil phase(s) comprises a first discontinuous phase, a second discontinuous phase and, optionally a third discontinuous phase comprising mineral oil, wherein the calcipotriol is predominantly in the first discontinuous phase,
5 wherein the betamethasone dipropionate is predominantly in the second discontinuous phase, and wherein the alpha-tocopherol and the butylated hydroxyanisole are predominantly in the first discontinuous phase, or predominantly in the first and second discontinuous phases collectively.
- 10 8. A composition according to claim 7, wherein the first discontinuous phase each comprise a pharmaceutically acceptable oil, wherein the pharmaceutically acceptable oil is a blend of caprylic capric triglycerides (CCT) and isopropyl myristate, and
15 wherein the isopropyl myristate and caprylic capric triglycerides are present in a weight ratio of from 3:1 to 12:1.
9. A composition according to any of the preceding claims, wherein the continuous aqueous phase comprises at least 4 wt% isopropanol by weight of the composition.
- 20 10. A composition according to any of the preceding claims, wherein the composition is chemically stable for at least 6 months at $25\text{ }^{\circ}\text{C} \pm 2\text{ }^{\circ}\text{C}$, as measured at $60\% \text{ RH} \pm 5\%$; and/or wherein the composition is chemically stable for at least 12 months at $5\text{ }^{\circ}\text{C} \pm 3$
25 $^{\circ}\text{C}$, as measured at $60\% \text{ RH} \pm 5\%$.
11. A composition for topical application comprising a polyaphron dispersion, the polyaphron dispersion comprising a continuous aqueous phase and at least one discontinuous oil phase,
30 wherein the polyaphron dispersion comprises calcipotriol, betamethasone dipropionate, alpha-tocopherol and butylated hydroxyanisole, wherein at least one of said discontinuous oil phase(s) comprises medium chain triglycerides and isopropyl myristate, and wherein the isopropyl myristate and medium chain triglycerides are present in a
35 weight ratio of from 3:1 to 12:1.
12. A composition for topical application comprising a polyaphron dispersion, wherein the polyaphron dispersion comprises:

- (i) calcipotriol;
- (ii) betamethasone or an ester thereof;
- (iii) alpha-tocopherol; and
- (iv) butylated hydroxyanisole.

5

13. A composition according to any of the preceding claims for use in a method of treatment of the human or animal body by therapy.

10

14. A composition according to any of claims 1 to 12 for use in the treatment of psoriasis.

15. A method of manufacturing a composition for topical application, the method comprising:

- (a) preparing a first polyaphron dispersion comprising calcipotriol, alpha-tocopherol and butylated hydroxyanisole;
- (b) preparing a second polyaphron dispersion comprising betamethasone dipropionate and preferably further comprising alpha-tocopherol and butylated hydroxyanisole; and

20 mixing together the first and second polyaphron dispersions to form the composition.

16. A method according to claim 15 further comprising:

- preparing a third polyaphron dispersion comprising a non-solvent oil, preferably wherein the non-solvent oil is mineral oil; and
- 25 mixing the third polyaphron dispersion with the first and second polyaphron dispersions to form the composition.

17. A composition obtainable by the method of claim 15 or claim 16.

30 18. Use of a combination of alpha-tocopherol and butylated hydroxyanisole in a composition for topical application to stabilise:

- (iii) calcipotriol; and/or
- (iv) betamethasone dipropionate.